Join to View Full Profile
3100 Plaza Properties BlvdColumbus, OH 43219
Phone+1 614-383-6000
Fax+1 614-383-6001
Dr. Patel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Taral Patel is an oncologist based in Columbus, OH, with extensive experience in gallbladder cancer, amyloidosis, cancer-associated retinopathy, hematologic oncology, and prostate cancer. He completed his residency in Internal Medicine at Cook County Health and Hospitals System and a Fellowship in Hematology and Medical Oncology at the University of Cincinnati Medical Center. He currently serves on the courtesy staff at OhioHealth Grant Medical Center, OhioHealth Grady Memorial Hospital, and Mount Carmel West. He is also a physician at Mid-Ohio Oncology/Hematology, Inc. Dr. Patel has been involved in multiple publications, including those in high-impact journals like The New England Journal of Medicine, and has contributed to clinical research involving percutaneous coronary interventions and oncology therapies.
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 1995 - 1998
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1992 - 1995
Baroda Medical CollegeClass of 1989
Certifications & Licensure
OH State Medical License 1998 - 2026
IL State Medical License 1992 - 1999
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 7 citationsDistal Radial Access in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the PROGRESS-CTO Registry.Ilias Nikolakopoulos, Taral Patel, Brian K. Jefferson, Abdul M. Sheikh, Wissam Jaber
The Journal of Invasive Cardiology. 2021-08-19 - 47 citationsProcedural Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions Via the Radial Approach: Insights From an International Chronic Total Occlusion...Peter Tajti, Khaldoon Alaswad, Dimitri Karmpaliotis, Farouc A. Jaffer, Robert W. Yeh
JACC. Cardiovascular Interventions. 2019-02-25 - 4 citationsEfficacy and Safety Results of the Afatinib Expanded Access ProgramEdward S. Kim, Balazs Halmos, Ingrid F. Kohut, Taral Patel, Regan D. Rostorfer
Oncology and Therapy. 2017-04-10
Abstracts/Posters
- Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who ar...Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm J, Hecht J, Perrou B, Griffing S, Nelson B, Novotny W, ASCO, Multiple Locations, 1/1/2004
- A Single Pegfilgrastim Dose Per Cycle Supports Dose-Dense (q14d) CHOP-R in Patients with NHLMoore T, Patel T, Segal M, Zangmeister J, Chidiac T, Roach R, Thompson M, Larrimer N., Journal of American Society of Hematology – Blood, 11/16/2002
- Second-Line Chemotherapy with Weekly Gemcitabine and Monthly Docetaxel in Patients with Metastatic Breast Cancer: A Phase II StudyLaufman LR, Spiridonidis CH, Carman L, Pritchard J, Roach R, Zangmeister J, Larrimer N, Jones J, Moore T, Segal M, Patel T, Gutterman L, Program/Proceedings of ASCO, Columbus, OH, 1/1/2000
- Join now to see all
Lectures
- Superior Vena Cava Syndrome: An Oncological Emergency1/1/1998
- Polycythemia. Hematology Oncology Lecture Series1/1/1998
- Case presentation of Locally Advanced Pancreatic Cancer Treated with GemcitabineDenver, CO - 1/1/1997
- Join now to see all
Press Mentions
American Oncology Network Partners with RxLightning to Speed Access to Specialty Medications for Cancer PatientsOctober 5th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
